Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2023-05-17 Capital/Financing Update
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Dividend Updates
Capital/Financing Update Classification · 95% confidence The document is a formal communication dated 17 May 2023 from Hester Biosciences Limited to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. It announces the approval of audited standalone and consolidated financial results for the quarter and year ended 31 March 2023, the recommendation of a dividend, and the re-appointment of the statutory auditor. It includes references to SEBI regulations and mentions that the audited financial results and auditor's reports are attached. The document is primarily an announcement of the board meeting outcomes and financial results approval, not the full financial report itself. The length is 4606 characters, which is relatively short and consistent with an announcement rather than a full report. It also includes a press release and mentions that an extract of results will be published in newspapers. This fits the profile of a Capital/Financing Update or Regulatory Filing, but since it includes audited financial results approval and dividend recommendation, it is best classified as a Capital/Financing Update (CAP). It is not a full Annual Report (10-K), nor an Earnings Release (ER) since it covers the full year and includes dividend and auditor re-appointment. It is not a Report Publication Announcement (RPA) because it contains substantive information rather than just announcing a report publication. Therefore, the best classification is CAP with high confidence.
2023-05-17 English
Dividend
Capital/Financing Update Classification · 90% confidence The document is a formal communication dated 17 May 2023 from Hester Biosciences Limited to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. It announces the approval of audited standalone and consolidated financial results for the quarter and year ended 31 March 2023, the recommendation of a dividend, and the re-appointment of the statutory auditor. The document includes references to SEBI regulations and contains an annexure with details about the auditor re-appointment. The document also mentions that the audited financial results and auditor's reports are attached, and a press release is issued. The document is relatively short (4606 characters) and primarily serves as an announcement of the board meeting outcomes, including financial results approval and dividend recommendation, rather than the full financial report itself. It does not contain the full financial statements or detailed financial analysis but rather the summary and official disclosures. Therefore, this document fits best under the category of Capital/Financing Update (CAP) because it includes dividend declaration and auditor re-appointment announcements related to financial results, or possibly Regulatory Filings (RNS) as a fallback. However, since it includes dividend recommendation and auditor re-appointment, which are capital and financing related updates, CAP is the most appropriate classification. Confidence is high due to clear references to dividend, auditor re-appointment, and financial results approval without the full report attached.
2023-05-17 English
Financial Result Updates
Regulatory Filings
2023-05-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification to stock exchanges about an upcoming earnings conference call scheduled for May 17, 2023, following the announcement of unaudited financial results for the quarter and year ended March 31, 2023. It includes details for joining the call and contact information but does not contain the financial results themselves or detailed financial data. The document is short (2134 characters) and serves as an announcement of the conference call event rather than the transcript or report of the call or financial results. Therefore, it fits the category of a Call Transcript announcement or notification. However, since it is only an intimation of the earnings conference call and not the transcript itself, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event.
2023-05-15 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It states that the promoters and promoter group have not made any encumbrance during the financial year ended 31 March 2023. This is a regulatory disclosure related to shareholding and encumbrance status, not a financial report or management discussion. The document is a formal notification to stock exchanges and does not contain financial statements or detailed analysis. It fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or declarations related to significant share ownership or encumbrances under SEBI regulations.
2023-05-09 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board Meeting scheduled for 17 May 2023. It mentions that the Board will consider audited financial results for the quarter and year ended 31 March 2023 and possibly declare dividends. The document is an intimation or announcement of a future event (Board Meeting) rather than the actual financial results or dividend declaration. It is also under 5,000 characters and serves as a regulatory disclosure under SEBI regulations. Therefore, it fits best under Board/Management Information (MANG) as it relates to a Board meeting announcement.
2023-05-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.